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To determine the impact of FDG-PET/CT in the initial staging of cervical cancer among
women with and without HIV and to determine the abilities of FDG-PET/CT metabolic
parameters in predicting the presence of distant metastasis.
Methods
We reviewed the FDG-PET/CT images of women with FIGO stage IB2 to IVA carcinoma of
the cervix. We compared the FIGO stage before and after FDG-PET/CT. Maximum and
mean standardized uptake values (SUVmax and SUVmean), metabolic tumor volume
(MTV) and total lesion glycolysis (TLG) of the primary lesion were determined. We com-
pared these parameters between the HIV-infected and uninfected woman and also deter-
mined their abilities to predict the presence of distant metastasis.
Results
126 women, mean age 48.05 ± 11.80 years were studied. Seventy-three patients were HIV-
infected. The disease was upstaged in 65 patients, 32 of which were upstaged to stage IVB.
HIV-infected women were younger (43.36 ± 8.03 years versus 54.51 ± 13.12, p<0.001) and
had more advanced disease (p = 0.022) compared with HIV-uninfected. In a univariate logis-
tic regression adjusted for the FIGO stage of the disease, there were significant associations
between MTV and TLG of the primary tumor and distant metastasis. SUVmax, SUVmean,
MTV and TLG performed well in predicting the presence of distant metastasis with areas
under the curves (AUCs) of 0.63, 0.66, 0.80 and 0.77 respectively. These performances
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improved after adjustment for the FIGO stage of the disease with AUCs of 0.80, 0.79, 0.84
and 0.82 for SUVmax, SUVmean, MTV and TLG respectively.
Conclusion
Inclusion of 18F-FDG-PET/CT in the pre-therapy assessment of cervical cancer improves
the accuracy of staging in about half of the patients. The metabolic parameters of the pri-
mary tumor perform well in predicting the presence of distant metastases.
Introduction
Carcinoma of the cervix is one of the most common gynecological malignancies and a signifi-
cant cause of cancer mortality worldwide [1–3]. Accurate staging is a necessary prerequisite to
determine the most appropriate therapeutic option. The staging of disease is done according
to the International Federation of Gynecology and Obstetrics (FIGO) recommendations [4].
FIGO staging entails a thorough pelvic examination, colposcopy, endocervical curettage, hys-
teroscopy, cystoscopy, proctoscopy, intravenous urography and radiological evaluation of the
lungs and skeleton for metastasis.
Hybrid positron emission tomography integrated with computed tomography using fluoro-
deoxyglucose (FDG-PET/CT) is an integrated metabolic and morphologic modality for onco-
logic imaging that outperforms stand-alone morphologic imaging. Metabolic parameters such
as maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV) and total
lesion glycolysis (TLG) derivable from FDG-PET/CT reflect the tumor metabolism and its
aggressiveness. These metabolic parameters have been shown to predict survival in different
malignancies [5]. Despite its excellent ability to detect the site of unknown metastasis in
patients with bulky primary tumor, FDG-PET/CT is still not routinely used for initial staging
of patients with carcinoma of the cervix. Lack of accurate staging of patients before the institu-
tion of therapy may result in ineffective treatment with its attendant morbidity and cost.
Carcinoma of the cervix has a strong association with persistent infection with high-risk
strains of human papillomavirus (HPV) infection, an oncogenic virus that predisposes to
high-grade intraepithelial lesions [6]. Individuals with human immunodeficiency virus
(HIV) infection have a higher prevalence of high-grade intraepithelial lesion and conse-
quently invasive squamous cell carcinoma (SCC) of the cervix [7,8]. Studies have shown the
utility of FDG-PET metabolic parameters in predicting distant metastasis as well as patients’
survival [9–11]. Most of these studies were done in countries with a low incidence of HIV
infection. It remains unknown if findings from these studies can be translated to HIV-associ-
ated invasive carcinoma of the cervix. The aim of this study was, therefore, to determine the
impact of FDG-PET/CT in the initial staging of a mixed population of women with and with-
out HIV infection diagnosed with carcinoma of the cervix as well as determine the abilities
of FDG-PET/CT metabolic parameters in predicting the presence of distant metastasis.
Materials and methods
Patients
We reviewed the FDG-PET/CT scan images of 519 consecutive patients with histological diag-
nosis of carcinoma of the cervix who were referred to the Department of Nuclear Medicine
at Steve Biko Academic Hospital in Pretoria from January 2014 to March 2018. Steve Biko
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Academic Hospital is one of the largest academic hospitals in South Africa that serve as a
referral center from most areas of two of the nine provinces of the country. The hospital also
receives referrals from other neighboring Southern African countries. We excluded patients
who obtained FDG-PET/CT scan for indications other than initial staging, those with FIGO
stages IA, IB1 and IVB disease, those in with vesicovaginal fistula complicating their disease
and technically sub-optimal scans. We reviewed the medical records of patients who met our
inclusion criteria to extract the following information: epidemiological parameters, FIGO
stage before FDG-PET imaging, histological sub-type of the tumor, and HIV status. In patients
with HIV infection, we extracted the CD 4 count and viral load. In our institution, patients
who are willing to allow their FDG-PET/CT imaging data to be used anonymously for research
purpose sign a consent form. We only used data from patients who had previously signed
this consent form in this study. The institutional review board of the University of Pretoria
approved this study (Reference No:223/2018).
FDG-PET/CT Imaging
A standard patient preparation was observed. Each patient fasted for a minimum of six hours
and fasting blood sugar was less than 11 mmol/L at the time of FDG injection. FDG was
injected intravenously with activity adjusted for patients’ weights. PET/CT imaging com-
menced 60 minutes following FDG administration. We performed imaging on a Biograph 40
Truepoint hybrid PET/CT scanner (Siemens Medical Solution, Illinois, USA). Where no con-
traindication existed, we imaged the patients with the administration of oral (Gastrografin,
Bayers, Isando, South Africa) and intravenous (Omnipaque, GE Healthcare, Wisconsin, USA)
contrast. We acquired PET images in 3D mode at 3 minutes per bed position in a caudocranial
direction. We performed PET image reconstruction using ordered subset expectation maximi-
zation iterative reconstruction (4 iterations, eight subsets) with a Gaussian filter applied at full-
width at half-maximum of 5.0mm.
Image analysis and interpretation
We performed image analysis and interpretation on a dedicated workstation equipped with a
Syngo.Via software (Siemens Medical Solution, Illinois, USA). We drew a semi-automatic
spherical volume of interest (VOI) around the primary cervical lesion while taking care to
exclude bladder, ureters and other areas of increased physiologic or pathologic FDG uptake.
We used an SUV threshold of 2.5 and a 3D isocontour of 41%. We recorded the SUVmax,
SUVmean, and MTV of the primary cervical lesions that were automatically computed by the
software. We manually computed the TLG of the primary cervical lesion by multiplying SUV-
mean by the MTV.
Two nuclear medicine physicians with five years (IOL) and more than ten years (MMS)
experience interpreting oncologic FDG-PET/CT images performed qualitative image interpre-
tation to determine, by consensus, the presence, and site of distant metastasis. Nodal metasta-
ses were classified as either pelvic nodes when localized to the pelvic region or extra-pelvic
nodes when localized elsewhere. We classified as visceral metastasis any metastatic lesion seen
in the soft tissue visceral (such as liver, lung, brain), peritoneum and peri-umbilical nodule.
We confirmed the findings on FDG-PET/CT as metastatic by histological examination in
64 patients. Where biopsy was not possible (n = 62), the findings were correlated with mag-
netic resonance imaging (MRI) or based on consensus interpretation by the interpreting
physicians.
We revised the FIGO staging following the confirmation of FDG-PET/CT findings. We deter-
mined the proportion of patients who had a FIGO stage migration following FDG-PET/CT.
FDG-PET metabolic metrics in cervical cancer
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Statistical analysis
We expressed continuous variables as the mean ± standard deviation (SD) when they were
normally distributed or as median (interquartile range, IQR) when they were skew. We
expressed categorical data as proportions (percentages). We used the Chi-square test to com-
pare categorical data, and the Mann Whitney U test and independent samples T-test for
continuous variables. We used logistic regression to determine the association between the
FDG-PET metabolic parameters and the presence of metastasis, first unadjusted, then adjusted
for FIGO stage of disease. We constructed adjusted ROC curves of SUVmax, SUVmean,
MTV, and TLG and reported the Area under the Curve (AUC). All statistical analyses were
two-tailed, and p-value<0.05 was considered statistically significant. Analyses were performed
using IBM SPSS Statistics 21.0 (IBM Corp, Armonk, New York USA) and STATA statistical
Software version 15 (College Station, TX: StataCorp LLC).
Results
A total of 126 women met our inclusion criteria and were included in this study, mean
age = 48.05 ± 11.80 years. There were 73 patients (57.9%) with HIV infection while 53 patients
(42.1%) were HIV-negative. About a half of our study population had a FIGO stage IIIB or
IVA disease at the time of referral for FDG-PET/CT. We found SCC as the most common his-
tological type of carcinoma of the cervix in our study population (87.3%). Other histological
variants seen included adenocarcinoma (7.9%), adenosquamous (1.6%), neuroendocrine
(1.6%) and other rare variants (1.6%). Table 1 shows the detailed baseline clinic-pathologic
characteristics of the study population.
Table 1. Clinical and pathologic characteristics of the study population.
Variable HIV + (n = 73) HIV–(n = 53) Overall (n = 126) p-value
Age (years)
Mean ± SD 43.36 ± 8.03 54.51 ± 13.12 48.05 ± 11.80 <0.001�
Range 25–82
FIGO stage
IB 19 (26.0) 8 (15.1) 27 (21.4) 0.022�
IIA 2 (2.7) 4 (7.5) 6 (4.8)
IIB 11 (15.1) 20 (37.7) 31 (24.6)
IIIB 38 (52.1) 19 (35.8) 57 (45.2)
IVA 3 (4.1) 2 (3.8) 5 (4.0)
Histology




Mixed squamous cell carcinoma, adenocarcinoma and neuroendocrine 1 (0.8)
Sarcomatoid
CD4 count (cells/uL)
Median (IQR) 480.0 (330.0–616.0) - -
Range 49–1190
Viral load (copies/mL)
Median (IQR) 132.50 (37.3–13388.0) - -
Range 21.0–52115.0
�: p-value <0.05; CD4: cluster of differentiation 4; HIV: human immunodeficiency virus; FIGO: International Federation of Gynecology and Obstetrics
https://doi.org/10.1371/journal.pone.0215412.t001
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FDG-PET/CT image findings
Following FDG-PET/CT scans, regional or distant metastases were seen in 88 patients
(69.8%). Among these 88 patients, metastases were localized to the pelvic nodes only in 27,
to extra-pelvic nodes only in five, to both pelvic and extra-pelvic nodes in 27, and to a combi-
nation of nodes and visceral organs in 18 patients. In one patient, metastasis was identified
in a visceral organ, in four patients to bone and lymph nodes, and to nodes, visceral organs,
and bone in 6 patients. Table 2 shows the detailed patients’ disease findings following the
FDG-PET/CT scan. Following FDG-PET/CT, 65 patients (51.6%) had a FIGO stage migration
to a higher stage (upstaged). Of 65 patients upstaged, 32 of them (49.2%) were upstaged to
stage IVB. Twenty-one of the patients upstaged to FIGO stage IVB were staged IIIB before
F-FDG-PET/CT, nine were from stage IIB and one each from stage 1B and stage IVA. In 25
patients, disease was upstaged to stage IVA. Invasion into the bladder or rectum was con-
firmed with MRI in 18 patients. The remaining patients proceeded to treatment based on FDG
PET/CT findings without further testing. No patient was down-staged following FDG-PET/
CT imaging. Table 3 shows details of stage migration in 65 patients that were upstaged.
Table 2. Disease characteristics of patients following FDG-PET/CT imaging.




Yes 51 (69.9) 37 (69.8) 88 (69.8) 0.995
No 22 (30.1) 16 (30.2) 38(30.2
Site of metastasis (n = 88)
Pelvic node only 18 (35.3) 9 (24.3) 27(30.7 0.404
Extrapelvic node only 2 (3.9) 3 (8.1) 5(5.7
Pelvic and extra-pelvic node 14 (27.5) 13 (35.1) 27(30.7
Visceral only 1 (2.0) 0 (0.0) 1(1.1
Node and visceral 9 (17.6) 9 (24.3) 18(20.5
Node and bone 4 (7.8) 0 (0.0) 4(4.5
Node, visceral and bone 3 (5.9) 3 (8.1) 6(6.8
Upstage Post PET
Yes 36 (49.3) 29 (54.7) 65(51.6) 0.549
No 37 (50.7) 24 (45.3) 61(48.4)
SUV max
Median (IQR) 18.66 (10.88–26.47) 21.12 (13.07–26.28) 19.5 (11.6–26.4) 0.194
Range 2.7–80.4
SUV mean
Median (IQR) 5.70 (4.26–7.35) 6.20 (4.48–7.65) 5.9 (4.3–7.5) 0.310
Range 1.9–18.8
MTV
Median (IQR) 224.35 (71.81–367.36) 177.91 (111.12–268.98) 188.8 (83.9–317.6) 0.588
Range 10.8–975.6
TLG
Median (IQR) 1355.97 (297.60–2700.47) 1164.06 (543.57–1921.49) 1227.9 (424.6–2376.7) 0.974
Range 29.9–8672.6
PET: Positron Emission Tomography; SUVmax: maximum Standardized Uptake Value; SUVmean: mean Standardized Uptake Value; MTV: Metabolic Tumor Volume;
TLG: Total Lesion Glycolysis
https://doi.org/10.1371/journal.pone.0215412.t002
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Comparison between HIV-infected and HIV-uninfected patients
The HIV- infected patients were significantly younger compared with HIV-uninfected
patients (43.36 ± 8.03 years versus 54.51 ± 13.12, p<0.001). More advanced diseases (higher
FIGO stages) were seen in HIV-infected patients compared with HIV-uninfected patients
(p = 0.022). For example, more than half of HIV-infected patients (56.2%) had a stage III or
IV disease compared with 39.6% of HIV-uninfected patients who had a stage III or IV dis-
ease. Among HIV-infected women, SCC was more prevalent compared with HIV-unin-
fected ones (p = 0.021). The proportion of patients with regional or distant metastases
were not significantly different between the HIV-infected group and HIV-uninfected
group. Similarly, the sites of metastases were not significantly different between HIV-
infected and HIV-uninfected patients. The proportion of patients who experienced FIGO
stage migration were not different between the two groups also. Similarly, FDG-PET meta-
bolic parameters (SUVmax, SUVmean, MTV and TLG) were not significantly different
between HIV-infected and HIV-uninfected women. Table 4 shows a detailed comparison
between HIV-infected and HIV-uninfected women. Among HIV-infected women, we
found no significant difference in the CD4 count or viral load between those women who
had regional or distant metastases compared to those with localized disease, p = 0.821 and
0.096 respectively.
The ability of FDG-PET Metabolic Parameters to Predict the Presence of
Distant Metastasis
SUVmax, SUVmean, MTV and TLG were all significantly higher among patients who had
distant metastases compared with those with localized disease, (p<0.05 in all cases), Table 5.
The univariable logistic regression showed that these parameters were also all significant in
their ability to predict the presence of distant metastasis, Table 6. After we adjusted for the
FIGO stage of the disease, only MTV and TLG remained significant predictors of distant
metastases. As these parameters increase, the probability of distant metastasis increases, as
indicated by the odds ratios being significantly greater than one. Using receiver operating
characteristic (ROC) curves, SUVmax, SUVmean, MTV and TLG performed well in predict-
ing the presence of distant metastasis with AUCs of 0.63 (95% CI: 0.52–0.74), 0.66 (95%CI:
0.56–0.77), 0.80 (95%CI: 0.71–0.88) and 0.77 (95%CI: 0.69–0.86) respectively. The perfor-
mance of these metabolic parameters in predicting distant metastasis improved after we
adjusted for the FIGO stage of the disease with AUCs of 0.80 (95%CI: 0.71–0.89), 0.79 (95%
CI: 0.69–0.88), 0.84 (95%CI: 0.76–0.92) and 0.82 (95%CI: 0.74–0.91) for SUVmax, SUV-
mean, MTV and TLG respectively (Fig 1a and 1b). Figs 2 and 3 show images of typical
patients we included in this study.
Table 3. A breakdown of FIGO stage migration in 65 patients who were upstaged.
FIGO Stage Post PET
FIGO stage IIA IIB IIIB IVA IVB
n (%) n (%) n (%) n (%) n (%)
IB (n = 5) 1 (20.0) 1 (20.0) 0 (0.0) 2 (40.0) 1 (20.0)
IIA (n = 2) 0 (0.0) 0 (0.0) 0 (0.0) 2 (100.0) 0 (0.0)
IIB (n = 20) 0 (0.0) 0 (0.0) 6 (30.0) 5 (25.0) 9 (45.0)
IIIB (n = 37) 0 (0.0) 0 (0.0) 0 (0.0) 16 (43.2) 21 (56.8)
IVA (n = 1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (100.0)
https://doi.org/10.1371/journal.pone.0215412.t003
FDG-PET metabolic metrics in cervical cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0215412 April 18, 2019 6 / 13
Discussion
We evaluated the ability of FDG-PET/CT to accurately stage women diagnosed with stages
IB to IVA carcinoma of the cervix and found FIGO stage migration to a higher disease state
in 51.6% of patients. Patients were upstaged following imaging due to a finding of a more
Table 4. A comparison between the clinical and the FDG-PET/CT image findings between HIV-infected and HIV-uninfected patients.
HIV
Variable Positive Negative χ2 p-value
n (%) n (%)
Age (years)
Mean ± SD 43.36 ± 8.03 54.51 ± 13.12 -5.902t <0.001�
FIGO stage
IB 19 (26.0) 8 (15.1) 8.988Y 0.022�
IIA 2 (2.7) 4 (7.5)
IIB 11 (15.1) 20 (37.7)
IIIB 38 (52.1) 19 (35.8)
IVA 3 (4.1) 2 (3.8)
Histology
Squamous cell carcinoma 68 (93.2) 42 (79.2) 5.356 0.021�
Others 5 (6.8) 11 (20.8)
Metastasis
Yes 51 (69.9) 37 (69.8) 0.000 0.995
No 22 (30.1) 16 (30.2)
Site of metastasis (n = 88)
Pelvic node only 18 (35.3) 9 (24.3) 2.509Y 0.404
Extrapelvic node only 2 (3.9) 3 (8.1)
Pelvic and extra-pelvic node 14 (27.5) 13 (35.1)
Visceral only 1 (2.0) 0 (0.0)
Node and visceral 9 (17.6) 9 (24.3)
Node and bone 4 (7.8) 0 (0.0)
Node, visceral and bone 3 (5.9) 3 (8.1)
Upstage Post PET
Yes 36 (49.3) 29 (54.7) 0.359 0.549
No 37 (50.7) 24 (45.3)
SUV max
Median (IQR) 18.66 (10.88–26.47) 21.12 (13.07–26.28) 1671.500U 0.194
SUV mean
Median (IQR) 5.70 (4.26–7.35) 6.20 (4.48–7.65) 1729.000U 0.310
MTV
Median (IQR) 224.35 (71.81–367.36) 177.91 (111.12–268.98) 1825.000U 0.588
TLG
Median (IQR) 1355.97 (297.60–2700.47) 1164.06 (543.57–1921.49) 1928.000U 0.974
PET: Positron Emission Tomography; SUVmax: maximum Standardized Uptake Value; SUVmean: mean Standardized Uptake Value; MTV: Metabolic Tumor Volume;
TLG: Total Lesion Glycolysis; χ2: Chi-square test;
Y: Yates Corrected Chi-square;
t: Independent Samples T-test;
U: Mann Whitney U test;
�: p-value <0.05;
https://doi.org/10.1371/journal.pone.0215412.t004
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extensive primary tumor than assessed clinically, detection of the urinary bladder or rectal
wall invasion or finding of a previously unknown site of distant metastasis. About half of the
patients (49.2%) who had stage migration were upstaged to FIGO stage IVB. This stage migra-
tion may significantly impact on patients’ management. It must be said however that not all
cases of stage migration may lead to a change in treatment option. Patients upstaged to stage
Table 5. The difference in FDG-PET metabolic parameters between patients with metastases and those without.
Metastasis
Variable Yes No U p-value
n (%) n (%)
SUV max
Median (IQR) 20.69 (12.97–26.67) 14.55 (7.87–24.53) 1223.500 0.017�
SUV mean
Median (IQR) 6.22 (4.93–8.02) 4.72 (3.32–6.79) 1123.000 0.004�
MTV
Median (IQR) 255.12 (129.18–382.03) 81.84 (40.78–187.75) 680.500 <0.001�
TLG
Median (IQR) 1619.36 (607.78–2751.69) 461.44 (153.73–1295.54) 759.000 <0.001�
SUVmax: maximum Standardized Uptake Value; SUVmean: mean Standardized Uptake Value; MTV: Metabolic Tumor Volume; TLG: Total Lesion Glycolysis; U:
Mann Whitney U test;
�: p-value <0.05
https://doi.org/10.1371/journal.pone.0215412.t005
Table 6. The ability of FDG-PET metabolic parameters unadjusted and adjusted for the FIGO stage of the disease to predict the presence of distant metastasis.
Unadjusted logistic regression Logistic regression adjusted for FIGO stage post PET
Variable OR(95%CI) p value AIC AUC OR(95%CI) p value AIC AUC
SUVmax 1.048(1.009–1.090) 0.016� 151.24 0.63(0.52–0.74) 1.031(0.992–1.0720) 0.121 128.65 0.80(0.71–0.89)
SUVmean 1.321(1.083–1.612) 0.006� 149.40 0.66(0.56–0.77) 1.072(0.861–1.337) 0.620 130.89 0.79(0.69–0.88)
MTV 1.009(1.005–1.014) <0.001� 127.81 0.80(0.71–0.88) 1.007(1.002–1.011) 0.003� 119.29 0.84(0.76–0.92)
TLG 1.0098(1.00048–1.00147) <0.001� 134.50 0.77(0.69–0.86) 1.00059(1.00012–1.00107) 0.014� 123.52 0.82(0.74–0.91)
SUVmax: maximum Standardized Uptake Value; SUVmean: mean Standardized Uptake Value; MTV: Metabolic Tumor Volume; TLG: Total Lesion Glycolysis; OR:
Odds Ratio; CI: Confidence Interval;
�: p-value <0.05
https://doi.org/10.1371/journal.pone.0215412.t006
Fig 1. Receiver operating characteristic curves unadjusted (a) and adjusted for FIGO stage of disease post PET/
CT imaging (b) showing the performance of FDG-PET metabolic parameters in predicting distant metastasis.
https://doi.org/10.1371/journal.pone.0215412.g001
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IVB due to the detection of a previously unknown sites of distant metastases would definitely
have a change in treatment option and intent, from a local/loco-regional treatment to systemic
and from a curative intent to palliative treatment intent. Accurate staging of disease is a pre-
requisite to determining the most suitable therapeutic option. Different stages of carcinoma of
the cervix are treated in different ways. Patients with early-stage disease may be offered radical
hysterectomy with or without lymphadenectomy followed by adjuvant therapy [12], while
patients with locally advanced disease are commonly treated with pelvic radiotherapy with or
without concurrent chemotherapy [13,14]. Patients with advanced disease (stage IVB) are
treated with single or combination chemotherapy [13]. We demonstrated the sites of metasta-
ses in 88 patients with the lymph nodes (pelvic and extra-pelvic) being the most common sites
Fig 2. FDG-PET/CT images of a 46-year-old HIV-infected female referred for imaging with stage IIB squamous
cell carcinoma of the cervix (SUVmax = 13.06, SUVmean = 4.22, MTV = 186.66, and TLG = 787.77). (A) Coronal
PET, (B) sagittal fused PET/CT, (C) axial PET and (D) axial fused PET/CT images show disease localized to the cervix
with no distant metastasis.
https://doi.org/10.1371/journal.pone.0215412.g002
Fig 3. FDG-PET/CT images of a 51-year-old HIV-uninfected female refereed with stage IIIB squamous cell
carcinoma of the cervix. (A) Coronal PET, (B) coronal fused PET/CT, (C) sagittal fused PET/CT and (D) axial PET,
CT and fused PET/CT images show local disease in the cervix (SUVmax = 24.7, SUVmean = 5.46, MTV = 182.01, and
TLG = 993.77) with distant metastasis to right-sided pelvic lymph node and the left ischial bone. She was upstaged to
stage IVB disease on account of ischial bone metastasis.
https://doi.org/10.1371/journal.pone.0215412.g003
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of metastases. The clinical importance of this is that the managing team can decide on the opti-
mum therapy among the available options and as well as guide the field of radiotherapy or
extent of surgery.
Among the 126 patients we included in this study, 57.9% had HIV infection. The HIV-
infected group was significantly younger and had a higher prevalence of FIGO stage III or IV
disease compared to the HIV-uninfected patients. The FDG-PET metabolic parameters, as
well as the pattern of distant spread, were not significantly different between the two groups.
Similarly, the proportion of patients who experienced stage migration was not significantly dif-
ferent from HIV-infected and HIV-uninfected women suggesting no difference in the impact
of FDG-PET/CT for initial staging of disease between the two groups. Detection of a previ-
ously unknown site of metastasis in the pelvis such as pelvic lymph node metastasis may lead
to a change in radiotherapy field in patients treated by radiotherapy alone or in combination
with chemotherapy [15]. These findings provide some guidance on the management of cervi-
cal cancer, an acquired immunodeficiency syndrome (AIDS)-defining cancer, among HIV-
infected patients. Cancer diagnosis at a younger age means that treatment must be offered
while minding the morbidity associated with cancer therapy that may impact on the quality of
life after that. Despite a higher prevalence of stage III and stage IV disease among HIV-infected
patients, we did not find any significant difference in the FDG-PET metabolic parameters in
them versus HIV-uninfected women. Since these parameters have prognostic implications,
this may suggest that stage for stage, HIV-infected patients and uninfected patients may be
treated in the same way while expecting a similar outcome. This finding is consistent with our
findings in other HIV-associated malignancies such as Hodgkin lymphoma and SCC of the
anus [16–18]. It also supports the recent recommendation of the National Comprehensive
Cancer Network (NCCN) advising that cancers may be treated similarly between HIV-infected
and uninfected patients in this current era of effective combination antiretroviral therapy
(ART) [19].
We compared the FDG-PET metabolic parameters of the primary tumor between patients
with metastases and those without metastasis and found significantly higher values for these
parameters in the former compared with the latter group. These parameters reflect the tumor
glucose metabolism and hence their aggressiveness [20]. MTV measures the volume of a
tumor bulk that is metabolically active. It is, therefore, better at predicting tumor biology than
a mere measurement of gross tumor volume that includes areas of necrosis and fibrosis within
the tumor bulk. In combination, these parameters have been found to predict response to ther-
apy as well as survival [10,11]. Presence of metastasis, especially to lymph nodes, is a significant
predictor of survival in patients with carcinoma of the cervix [11]. All the metabolic parameters
we tested in the unadjusted model were significant in predicting the presence of distant metas-
tasis. The probability of metastasis is influenced by the primary tumor size with larger tumors
more likely to be associated with distant tumor spread. We, therefore, subsequently adjusted
for the FIGO stage of the disease while evaluating the ability of the metabolic parameters for
the presence of distant metastasis. Following this adjustment, only MTV and TLG remained
significant predictors of distant metastasis. Our findings show that MTV and TLG are more
robust in their ability to reflect the tumor behavior compared with SUVmax and SUVmean.
Other authors have also reported the correlation between FDG-PET metabolic parameters and
nodal metastasis. In a recent study, Zhang et al. found MTV and TLG but not SUVmax to be
significant predictors of lymph node metastasis [20]. These workers evaluated only patients
with early-stage carcinoma of the cervix (FIGO IB1—IIA) unlike our study with a more hetero-
geneous patient population. Also, it is unknown if their study population included patients
with HIV infection. Chung and colleagues, however, found a significant correlation between
SUVmax and nodal metastasis in a group of patients with stage IB to IIA disease [21].
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Our study included patients who are typically referred for imaging in cervical cancer stag-
ing. We excluded patients with stage IA and IB1 disease as the volume of disease is small in
these patients. Small lesions suffer from partial volume averaging leading to an underestima-
tion of the FDG-PET metabolic parameters. We also excluded patients with stage IV disease at
the time of referral as these patients were already known with advanced disease and had no sig-
nificant benefit from imaging.
One of the strengths of our study lies in the unique population we studied, a mix of HIV-
infected and HIV-uninfected patients. Even in the current ART era, HIV-associated malignan-
cies remain an increasing cause of mortality among individuals affected with this virus in
developed and developing countries alike [22,23]. It is, therefore, necessary to determine the
performance of FDG-PET/CT in accurate staging and its metabolic parameters in the determi-
nation of the presence of distant metastases among HIV-infected individuals with carcinoma
of the cervix.
The results from our results need to be interpreted with bearing in mind the limitations
therein. The disease was upstaged in about half of the study population. This high proportion
of patients who had stage migration may be as a result of selection bias where patients with sus-
picion of distant metastasis were more likely to undergo FDG-PET/CT scan compared with
patients in whom clinically staging was done with more certainty. Not all lesions seen on
FDG-PET/CT were confirmed by histological evaluation as metastatic. This will be impractica-
ble and unethical especially in patients with multiple sites of lesions. Evaluation for distant
metastases was based on the histological confirmation, correlative imaging with MRI and the
experience of the interpreting physicians. The retrospective design of our study is another lim-
itation. As a result of the retrospective design of this study, we do not have sufficient informa-
tion on how these patients would have being managed if they had not had FDG-PET/CT
imaging preventing us from reporting on the impact of stage migration on patients’ manage-
ment. A prospectively designed trial confirming our results will be necessary in the future. A
phase III trial that compared the role of FDG-PET/CT with stand-alone CT in the initial stag-
ing of women with cervical cancer recently reported its findings [24]. The study was under-
powered and was terminated due to poor patient recruitment.
Conclusion
In women with cervical carcinoma, the inclusion of FDG-PET/CT in the pre-therapy assessment
improved the accuracy of staging in about of half of patients. FDG-PET metabolic metrics can
accurately predict individuals with distant metastases. These metabolic parameters and pattern
of metastases are not significantly different between HIV-infected and HIV-uninfected patients.
Supporting information
S1 Table. Supporting information.
(XLSX)
Acknowledgments
We thank all members of staff at the Department of Nuclear Medicine, Steve Biko Academic
Hospital for their various contributions to this work.
Author Contributions
Conceptualization: Ismaheel O. Lawal, Alfred O. Ankrah, Mike M. Sathekge.
FDG-PET metabolic metrics in cervical cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0215412 April 18, 2019 11 / 13
Data curation: Ismaheel O. Lawal.
Formal analysis: Charl Janse van Rensburg, Gbenga O. Popoola.
Investigation: Ismaheel O. Lawal.
Methodology: Ismaheel O. Lawal, Thabo Lengana, Florette Reyneke, Alfred O. Ankrah, Mike
M. Sathekge.
Project administration: Ismaheel O. Lawal, Mike M. Sathekge.
Resources: Mike M. Sathekge.
Validation: Ismaheel O. Lawal.
Writing – original draft: Ismaheel O. Lawal, Charl Janse van Rensburg, Alfred O. Ankrah.
Writing – review & editing: Ismaheel O. Lawal, Thabo Lengana, Charl Janse van Rensburg,
Florette Reyneke, Gbenga O. Popoola, Alfred O. Ankrah, Mike M. Sathekge.
References
1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2018. CA Cancer J Clin. 2018; 68: 7–30. https://doi.
org/10.3322/caac.21442 PMID: 29313949
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLO-
BOCAN estimates of incidence and mortality for 36 cancers in 185 countries. CA Cancer J Clin. 2018;
68: 394–424. https://doi.org/10.3322/caac.21492
3. Yamagami W, Nagase S, Takahashi F, Ino K, Hachisuga T, Aoki D, et al. Clinical statistics of gyneco-
logic cancers in Japan. J Gynecol Oncol. 2017; 28: e32. https://doi.org/10.3802/jgo.2017.28.e32 PMID:
28198168
4. FIGO Committee on Gynecologic Oncology. Revised FIGO staging for carcinoma of the vulva, cervix,
and endometrium. Int J Gynecol Obstet. 2009; 105: 103–104.
5. Van de Wiele C, Kruse V, Smeets P, Sathekge M, Maes A. Predictive and prognostic value of metabolic
tumour volume and total lesion glycolysis in solid tumours. Eur J Nucl Med Mol Imaging. 2013; 40: 290–
301. https://doi.org/10.1007/s00259-012-2280-z PMID: 23151913
6. de Martel C, Plummer M, Vignat J, Franceshi S. Worldwide burden of cancer attributable to HPV by
site, country and HPV type. Int J Cancer. 2017; 141: 664–670. https://doi.org/10.1002/ijc.30716 PMID:
28369882
7. Orlando G, Bianchi S, Fasolo MM, Mazza F, Frati ER, Rizzardini G, et al. Cervical human papillomavi-
rus genotypes in HIV-infected women: a cross-sectional analysis of the VALHIDATE study. J Prev Med
Hyg. 2017; 58: E259–265. https://doi.org/10.15167/2421-4248/jpmh2017.58.4.804 PMID: 29707656
8. Mudini W, Palefsky JM, Hale MJ, Chiranje MZ, Makunike-Mutasa RT, Mutisi F, et al. Human papilloma-
virus genotypes in invasive cervical carcinoma in HIV seropositive and seronegative women in Zimba-
bwe. J Acquir Immune Defic Syndr. 2018; 79: e1–e6. https://doi.org/10.1097/QAI.0000000000001754
9. Kidd EA, Siegel BA, Dehdashti F, Grigsby PR. The Standardized Uptake Value for F-18 Fluorodeoxy-
glucose Is a Sensitive Predictive Biomarker for Cervical Cancer Treatment Response and Survival.
Cancer. 2007; 110: 1738–44. https://doi.org/10.1002/cncr.22974 PMID: 17786947
10. Herrera FG, Breuneval T, Prior JO, Bourhis J, Ozsahin M. [18F]FDG-PET/CT metabolic parameters as
useful prognostic factors in cervical cancer patients treated with chemo-radiotherapy. Radiat Oncol.
2016; 11: 43. https://doi.org/10.1186/s13014-016-0614-x PMID: 26984385
11. Kidd EA, El Naqa I, Siegel BA, Dehdshti F, Grigsby PW. FDG-PET-based prognostic nomograms for
locally advanced cervical cancer. Gynecol Oncol. 2012; 127: 136–40. https://doi.org/10.1016/j.ygyno.
2012.06.027 PMID: 22735785
12. Lee KW, Shim SH, Lee JM. Comparison between adjuvant chemotherapy and adjuvant radiotherapy/
chemotherapy after radical surgery in patients with cervical cancer: a meta-analysis. J Gynecol Oncol.
2018; 29: e62. https://doi.org/10.3802/jgo.2018.29.e62
13. Chuang LT, Temin S, Camacho R, Dueñas-Gonzalez A, Feldman S, Gultekin M, et al. Management
and Care of Women With Invasive Cervical Cancer: American Society of Clinical Oncology Resource-
Stratified Clinical Practice Guideline. J Glob Oncol. 2016; 2: 311–40. https://doi.org/10.1200/JGO.2016.
003954 PMID: 28717717
FDG-PET metabolic metrics in cervical cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0215412 April 18, 2019 12 / 13
14. Mabuchi S, Isohashi F, Okazawa M, Kitada F, Maruoka S, Ogawa K, et al. Chemoradiotherapy followed
by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical
cancer patients. J Gynecol Oncol. 2017; 28: e15. https://doi.org/10.3802/jgo.2017.28.e15 PMID:
27958682
15. Al-Ibraheem A, AlSharif A, Abu-Hijih R, Jaradat I, Mansour A. Clinical impact of 18F-FDG PET/CT on
the management of gynecologic cancers: One center experience. Asia Ocean J Nucl Med Biol. 2019;
7:7–12. https://doi.org/10.22038/AOJNMB.2018.11208 PMID: 30705906
16. Lawal IO, Nyakale NE, Harry LM, Modiselle MR, Ankrah AO, Msomi AP, et al. The role of F-18 FDG
PET/CT in evaluating the impact of HIV infection on tumor burden and therapy outcome in patients with
Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2017; 44: 2025–2033. https://doi.org/10.1007/
s00259-017-3766-5 PMID: 28660348
17. Lawal IO, Ankrah AO, Popoola GO, Nyakale NE, Boshomane TG, Reyneke F, et al. 18F-FDG-PET
metabolic metrics and International Prognostic Score for risk assessment in HIV-infected patients with
Hodgkin lymphoma. Nucl Med Commun. 2018; 39: 1005–1012. https://doi.org/10.1097/MNM.
0000000000000905 PMID: 30198974
18. Lawal IO, Ankrah AO, Mokoala KMG, Popoola GO, Kaoma CA, Maes A, et al. Prognostic Value of Pre-
treatment F-18 FDG PET Metabolic Metrics in Patients with Locally Advanced Carcinoma of the Anus
with and without HIV infection. Nuklearmedicine. 2018; 57: 190–197.
19. NCCN Clinical Practice Guideline in Oncology-Cancer in People Living with HIV. Version 1.2018.
https://www.nccn.org/professionals/physician_gls/default.aspx on 27 December, 2018.
20. Zhang L, Sun H, Du S, Xu W, Xin J, Guo Q. Evaluation of 18F-FDG PET/CT parameters for reflecting
aggressiveness and prediction of prognosis in early-stage cervical cancer. Nucl Med Commun. 2018;
39: 1045–1052. https://doi.org/10.1097/MNM.0000000000000909
21. Chung HH, Kim JW, Han KH, Eo JS, Kang KW, Park NH, et al. Prognostic value of metabolic tumour
volume measured by FDG-PET/CT in patients with cervical cancer. Gynecol Oncol. 2011; 120: 270–
274. https://doi.org/10.1016/j.ygyno.2010.11.002
22. Vandenhende MA, Roussillon C, Henard S, Mariat P, Oksenhendler E, Aumaitre H, et al. Cancer-
Related Causes of Death among HIV-Infected Patients in France in 2010: Evolution since 2000. PLoS
ONE. 2015; 10: e0129550. https://doi.org/10.1371/journal.pone.0129550 PMID: 26083524
23. Domingues CSB, Waldman EA. Causes of Death among People Living with AIDS in the Pre- and Post-
HAART Eras in the City of São Paulo, Brazil. PLoS ONE. 2014; 9: e114661.
24. Elit LM, Fyles AW, Gu CS, Pond GR, D’Souza D, Samant R, et al. Effect of Positron Emission Tomogra-
phy in Women With Locally Advanced Cervical Cancer: A Randomized Clinical Trial. JAMA Network
Open. 2018; 1: e182081. https://doi.org/10.1001/jamanetworkopen.2018.2081
FDG-PET metabolic metrics in cervical cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0215412 April 18, 2019 13 / 13
